A study found that the difficulty of surgery and the degree of cancer spread in the abdominal cavity can be predicted only by ...

A management strategy for women with recurrent ovarian cancer has been called into question after data from a prospective clinical trial showed no benefit and, indeed, suggested harm. The strategy is ...

An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.

The Food and Drug Administration has approved a new drug that will help surgeons while they're removing ovarian cancer. Cytalux was developed by Purdue University. It is an imaging agent that will ...

Inherited changes in the tumor suppressor genes BRCA1 and BRCA2, raise lifetime risk substantially. For ovarian cancer, the ...

There’s been an ongoing conversation about the importance of listening to your body, and Marsai Martin is one of the latest celebs echoing this message. The Black-ish star opened up about the ovarian ...

Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions. The Food and Drug Administration (FDA) has approved Cytalux™ (pafolacianine), an optical imaging agent, ...

—This study explores factors associated with complications and survival among women with epithelial ovarian cancer who undergo primary debulking surgery. Reviewed by Vrunda Bhavsar Desai, MD, FACOG, ...

Navigating the treatment of a deadly form of cancer can be not just physically, but emotionally exhausting. Finding out the ...

For most women, menopause occurs naturally around the age of 49. In the lead up to menopause, the quality and quantity of ...

ISTANBUL, TR / ACCESS Newswire / November 25, 2025 / Robotic surgery is transforming the landscape of modern medicine. With ...

Ovarian cancer patient Carol Giandonato admits to being apprehensive when her oncologist told her he wanted to make her cancer cells turn fluorescent green. “Am I going to glow in the dark? Will I be ...